Pharm-Olam completes a Phase III Pulmonary Arterial Hypertension study
Pharm-Olam was selected to provide development services for a Phase III study, which was designed to address the efficacy and safety for a compound for pulmonary arterial hypertension patients.
Pharm-Olam was responsible for:
- The recruitment of 192 patients
- Management of 17 sites in Russia, Belarus, and Ukraine
- All regulatory, project management, and monitoring services
To view the case study and the lessons learned in this study, click here